PD-1/PD-L1
Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.
Trovati 139 prodotti di "PD-1/PD-L1"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS:<p>Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.</p>Purezza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Colore e forma:LiquidDurvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purezza:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:146.03 kDaSintilimab
CAS:<p>Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.</p>Purezza:> 95%Colore e forma:LiquidPeso molecolare:144.04 kDaZimberelimab
CAS:<p>Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.</p>Purezza:95%Colore e forma:LiquidSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purezza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Colore e forma:LiquidPeso molecolare:145.74 kDaBudigalimab
CAS:<p>Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.</p>Purezza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Colore e forma:LiquidAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purezza:95.07%Colore e forma:SolidPeso molecolare:3321.61BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purezza:97.36%Colore e forma:SolidPeso molecolare:631.11Tislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purezza:95.07%Colore e forma:LiquidEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purezza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Colore e forma:LiquidDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purezza:>95%Colore e forma:LiquidManelimab
CAS:<p>Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .</p>Colore e forma:LiquidPD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Colore e forma:Odour SolidPidilizumab
CAS:Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologicPurezza:98%Colore e forma:LiquidHuman PD-L1 inhibitor III
CAS:<p>Human PD-L1 inhibitor III is a human PD-L1 inhibitor.</p>Formula:C97H155N29O29SColore e forma:SolidPeso molecolare:2223.54Moflerafusp alfa
CAS:Moflerafusp alfa is a fusion protein that targets the human signal-regulatory protein alpha (SIRPα) variant V2 D1 domain and human programmed death-ligand 1 (PD-L1). It shows potential for research in various cancer treatments.Colore e forma:LiquidEciskafusp alfa
CAS:<p>Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specific</p>Purezza:98%Colore e forma:SolidPacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Purezza:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Colore e forma:LiquidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurezza:98%Colore e forma:SolidCamrelizumab
CAS:<p>Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up</p>Purezza:95% - 98.6%Colore e forma:LiquidPeso molecolare:143.7 kDaVolrustomig
CAS:Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.Colore e forma:LiquidLedostomig
CAS:<p>Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody that targets human neurotensin receptor type 5 (NTS5) and programmed death-1 (PD-1). It shows potential for research in various cancer types.</p>Colore e forma:LiquidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Colore e forma:SolidPeso molecolare:2602.69Zeluvalimab
CAS:Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].Colore e forma:LiquidBMSpep-57
CAS:BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formula:C89H126N24O19SColore e forma:SolidPeso molecolare:1868.2Finotonlimab
Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].Colore e forma:Odour LiquidSudubrilimab
Sudubrilimab (HS636) is an IgG1-κ monoclonal antibody targeting PDL1, fused with TGFBR2-ECD to block PD-1/PDL1 and TGF-β in tumors.Colore e forma:Odour LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Colore e forma:Odour LiquidLorigerlimab
CAS:Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.Colore e forma:LiquidAnti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
<p>Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.</p>Colore e forma:Odour LiquidOPBP-1
<p>OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.</p>Formula:C64H92N20O19SPeso molecolare:1476.65683Nofazinlimab
CAS:<p>Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).</p>Purezza:98.6% (SDS-PAGE); 99.7% (SEC-HPLC) - 98.6% (SDS-PAGE); 99.7% (SEC-HPLC)Colore e forma:LiquidPD-L1-IN-5
<p>PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.</p>Opucolimab
CAS:<p>Opucolimab is a human antibody targeting PD-L1, used in advanced solid tumor research and antibody-drug conjugate synthesis.</p>Colore e forma:LiquidPD-1/PD-L1-IN-49
<p>PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.</p>Formula:C27H32N4O5Colore e forma:SolidPeso molecolare:492.567PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formula:C23H20ClFN2O3Peso molecolare:426.11465Betifisolimab
CAS:Betifisolimab (MSB-2311) is a humanized antibody targeting PD-L1 for solid tumors and blood cancer research.Colore e forma:LiquidAUNP-12
CAS:AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formula:C142H226N40O48Purezza:98%Colore e forma:SolidPeso molecolare:3261.55Lodapolimab
CAS:<p>Lodapolimab (LY3300054) is an IgGλ anti- PD-1 monoclonal antibody [1] .</p>Colore e forma:LiquidPD-1/PD-L1-IN-52
<p>PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.</p>Colore e forma:Odour SolidPimivalimab
CAS:<p>Pimivalimab (JTX-4014), a PD-1 inhibitor, is utilized in solid tumor research [1].</p>Colore e forma:LiquidPD-L1 inhibitory peptide
CAS:PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formula:C96H135N21O23SColore e forma:SolidPeso molecolare:1983.29PD-L1/VISTA-IN-2
<p>PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.</p>Formula:C22H22N2O3Colore e forma:SolidPeso molecolare:362.42Balstilimab
CAS:<p>Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .</p>Colore e forma:LiquidIparomlimab
CAS:Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.Colore e forma:LiquidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purezza:99.92%Colore e forma:SolidPeso molecolare:348.44TQB-2858
<p>TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).</p>Colore e forma:Odour LiquidPD-1/PD-L1-IN-48
<p>PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.</p>Colore e forma:Odour SolidHuman PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Colore e forma:SolidPeso molecolare:2350.576Human PD-L1 inhibitor II
CAS:Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formula:C103H151N25O30Colore e forma:SolidPeso molecolare:2219.486
